Losartan increases bone mass and accelerates chondrocyte hypertrophy in developing skeleton

Molecular Genetics and Metabolism

Volumn 115, Issue 1, 2015, Pages 53-60

  Chen, Shan ^f   Grover, Monica ^a   Sibai, Tarek ^b   Black, Jennifer ^c   Rianon, Nahid ^d   Rajagopal, Abbhirami ^a   Munivez, Elda ^a   Bertin, Terry ^a   Dawson, Brian ^a   Chen, Yuqing ^a   Jiang, Ming Ming ^a   Lee, Brendan ^a   Yang, Tao ^e   Bae, Yangjin ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^e VAN ANDEL RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

ARB; Chondrocyte; ERK phosphorylation; Losartan; Osteoclasts; RANKL

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN II; COLLAGEN; COLLAGEN 10A1; LOSARTAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OSTEOCLAST DIFFERENTIATION FACTOR; UNCLASSIFIED DRUG; ANGIOTENSIN DERIVATIVE; TNFSF11 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ATTENUATION; BIRTH; BONE DENSITY; BONE DEVELOPMENT; BONE MASS; CARTILAGE; CARTILAGE CELL; CELL ADHESION; CELL LINE; CELL PROLIFERATION; CHONDROCYTE HYPERTROPHY; CHONDROPATHY; CONCEPTION; CONTROLLED STUDY; CORTICAL THICKNESS (BONE); DRUG EFFICACY; GROWTH PLATE; HYPERTROPHY; IN VITRO STUDY; IN VIVO STUDY; MALE; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKELETON; TRABECULAR BONE; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE; C57BL MOUSE; CELL DIFFERENTIATION; CHONDROCYTE; DIAGNOSTIC IMAGING; DRUG EFFECTS; EPIPHYSIS PLATE; FEMALE; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; RADIOGRAPHY; RAW 264.7 CELL LINE; ULTRASTRUCTURE;

ANIMALIA; MUS;

ANGIOTENSINS; ANIMALS; BONE AND BONES; BONE DENSITY; BONE DEVELOPMENT; CARTILAGE; CELL DIFFERENTIATION; CHONDROCYTES; FEMALE; GROWTH PLATE; HYPERTROPHY; LOSARTAN; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; OSTEOCLASTS; PHOSPHORYLATION; RADIOGRAPHY; RANK LIGAND; RAW 264.7 CELLS;

EID: 84933677925     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2015.02.006     Document Type: Article

References (38)

1. Chiu H.H., Wu M.H., Wang J.K., Lu C.W., Chiu S.N., et al. Losartan added to beta-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study. Mayo Clin. Proc. 2013, 88:271-276.
2. Habashi J.P., Judge D.P., Holm T.M., Cohn R.D., Loeys B.L., et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006, 312:117-121.
3. Gross O., Kashtan C.E. Treatment of Alport syndrome: beyond animal models. Kidney Int. 2009, 76:599-603.
4. Grover M., Brunetti-Pierri N., Belmont J., Phan K., Tran A., et al. Assessment of bone mineral status in children with Marfan syndrome. Am. J. Med. Genet. A 2012, 158A:2221-2224.
5. Giampietro P.F., Peterson M.G., Schneider R., Davis J.G., Burke S.W., et al. Bone mineral density determinations by dual-energy X-ray absorptiometry in the management of patients with Marfan syndrome-some factors which affect the measurement. HSS J. 2007, 3:89-92.
6. Moura B., Tubach F., Sulpice M., Boileau C., Jondeau G., et al. Bone mineral density in Marfan syndrome. A large case-control study. Joint Bone Spine 2006, 73:733-735.
7. Zaman M.A., Oparil S., Calhoun D.A. Drugs targeting the renin-angiotensin-aldosterone system. Nat. Rev. Drug Discov. 2002, 1:621-636.
8. Ma L., Ji J.L., Ji H., Yu X., Ding L.J., et al. Telmisartan alleviates rosiglitazone-induced bone loss in ovariectomized spontaneous hypertensive rats. Bone 2010, 47:5-11.
9. Izu Y., Mizoguchi F., Kawamata A., Hayata T., Nakamoto T., et al. Angiotensin II type 2 receptor blockade increases bone mass. J. Biol. Chem. 2009, 284:4857-4864.
10. Shimizu H., Nakagami H., Osako M.K., Hanayama R., Kunugiza Y., et al. Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J. 2008, 22:2465-2475.
11. Garcia P., Schwenzer S., Slotta J.E., Scheuer C., Tami A.E., et al. Inhibition of angiotensin-converting enzyme stimulates fracture healing and periosteal callus formation - role of a local renin-angiotensin system. Br. J. Pharmacol. 2010, 159:1672-1680.
12. Tsubakimoto Y., Yamada H., Yokoi H., Kishida S., Takata H., et al. Bone marrow angiotensin AT1 receptor regulates differentiation of monocyte lineage progenitors from hematopoietic stem cells. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1529-1536.
13. Mannisto T.K., Karvonen K.E., Kerola T.V., Ryhanen L.J. Inhibitory effect of the angiotensin converting enzyme inhibitors captopril and enalapril on the conversion of procollagen to collagen. J. Hypertens. 2001, 19:1835-1839.
14. Kawakami Y., Matsuo K., Murata M., Yudoh K., Nakamura H., et al. Expression of angiotensin II receptor-1 in human articular chondrocytes. Arthritis 2012, 2012:648537.
15. Cohn R.D., van Erp C., Habashi J.P., Soleimani A.A., Klein E.C., et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat. Med. 2007, 13:204-210.
16. Yang T., Grafe I., Bae Y., Chen S., Chen Y., et al. E-selectin ligand 1 regulates bone remodeling by limiting bioactive TGF-beta in the bone microenvironment. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:7336-7341.
17. Engin F., Yao Z., Yang T., Zhou G., Bertin T., et al. Dimorphic effects of Notch signaling in bone homeostasis. Nat. Med. 2008, 14:299-305.
18. Napierala D., Sam K., Morello R., Zheng Q., Munivez E., et al. Uncoupling of chondrocyte differentiation and perichondrial mineralization underlies the skeletal dysplasia in tricho-rhino-phalangeal syndrome. Hum. Mol. Genet. 2008, 17:2244-2254.
19. Reuter S., Gupta S.C., Phromnoi K., Aggarwal B.B. Thiocolchicoside suppresses osteoclastogenesis induced by RANKL and cancer cells through inhibition of inflammatory pathways: a new use for an old drug. Br. J. Pharmacol. 2012, 165:2127-2139.
20. Hsu H., Lacey D.L., Dunstan C.R., Solovyev I., Colombero A., et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:3540-3545.
21. Higuchi S., Ohtsu H., Suzuki H., Shirai H., Frank G.D., et al. Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. Clin. Sci. (Lond.) 2007, 112:417-428.
22. Wada T., Nakashima T., Hiroshi N., Penninger J.M. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol. Med. 2006, 12:17-25.
23. Lamothe B., Webster W.K., Gopinathan A., Besse A., Campos A.D., et al. TRAF6 ubiquitin ligase is essential for RANKL signaling and osteoclast differentiation. Biochem. Biophys. Res. Commun. 2007, 359:1044-1049.
24. Lee Z.H., Kim H.H. Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem. Biophys. Res. Commun. 2003, 305:211-214.
25. Cortez-Retamozo V., Etzrodt M., Newton A., Ryan R., Pucci F., et al. Angiotensin II drives the production of tumor-promoting macrophages. Immunity 2013, 38:296-308.
26. Fukuda D., Sata M. Role of bone marrow renin-angiotensin system in the pathogenesis of atherosclerosis. Pharmacol. Ther. 2008, 118:268-276.
27. Haznedaroglu I.C., Ozturk M.A. Towards the understanding of the local hematopoietic bone marrow renin-angiotensin system. Int. J. Biochem. Cell Biol. 2003, 35:867-880.
28. Kaneko K., Ito M., Fumoto T., Fukuhara R., Ishida J., et al. Physiological function of the angiotensin AT1a receptor in bone remodeling. J. Bone Miner. Res. 2011, 26:2959-2966.
29. Zhang Y., Diao T.Y., Gu S.S., Wu S.Y., Gebru Y.A., et al. Effects of angiotensin II type 1 receptor blocker on bones in mice with type 1 diabetes induced by streptozotocin. J. Renin-Angiotensin-Aldosterone Syst. 2013, 2.
30. Donmez B.O., Ozdemir S., Sarikanat M., Yaras N., Koc P., et al. Effect of angiotensin II type 1 receptor blocker on osteoporotic rat femurs. Pharmacol. Rep. 2012, 64:878-888.
31. Asaba Y., Ito M., Fumoto T., Watanabe K., Fukuhara R., et al. Activation of renin-angiotensin system induces osteoporosis independently of hypertension. J. Bone Miner. Res. 2009, 24:241-250.
32. Luft F.C., Dechend R., Muller D.N. Immune mechanisms in angiotensin II-induced target-organ damage. Ann. Med. 2012, 44(Suppl. 1):S49-S54.
33. de Lange-Brokaar B.J., Ioan-Facsinay A., van Osch G.J., Zuurmond A.M., Schoones J., et al. Synovial inflammation, immune cells and their cytokines in osteoarthritis: a review. Osteoarthr. Cartil. 2012, 20:1484-1499.
34. Dagenais N.J., Jamali F. Protective effects of angiotensin II interruption: evidence for antiinflammatory actions. Pharmacotherapy 2005, 25:1213-1229.
35. Tsukamoto I., Inoue S., Teramura T., Takehara T., Ohtani K., et al. Activating types 1 and 2 angiotensin II receptors modulate the hypertrophic differentiation of chondrocytes. FEBS Open Bio 2013, 3:279-284.
36. Sukumaran V., Watanabe K., Veeraveedu P.T., Thandavarayan R.A., Gurusamy N., et al. Telmisartan, an angiotensin-II receptor blocker ameliorates cardiac remodeling in rats with dilated cardiomyopathy. Hypertens. Res. 2010, 33:695-702.
37. Odenbach J., Wang X., Cooper S., Chow F.L., Oka T., et al. MMP-2 mediates angiotensin II-induced hypertension under the transcriptional control of MMP-7 and TACE. Hypertension 2011, 57:123-130.
38. Nagasawa A., Yoshimura K., Suzuki R., Mikamo A., Yamashita O., et al. Important role of the angiotensin II pathway in producing matrix metalloproteinase-9 in human thoracic aortic aneurysms. J. Surg. Res. Jul. 2013, 183(1):472-477.